HRP20221183T1 - T-stanični receptori anti-kras-g12d - Google Patents

T-stanični receptori anti-kras-g12d Download PDF

Info

Publication number
HRP20221183T1
HRP20221183T1 HRP20221183TT HRP20221183T HRP20221183T1 HR P20221183 T1 HRP20221183 T1 HR P20221183T1 HR P20221183T T HRP20221183T T HR P20221183TT HR P20221183 T HRP20221183 T HR P20221183T HR P20221183 T1 HRP20221183 T1 HR P20221183T1
Authority
HR
Croatia
Prior art keywords
seq
amino acid
acid sequence
isolated
polypeptide chain
Prior art date
Application number
HRP20221183TT
Other languages
English (en)
Croatian (hr)
Inventor
Eric TRAN
Yong-Chen LU
Paul F. Robbins
Steven A. Rosenberg
Zhili ZHENG
Original Assignee
The U.S.A. As Represented By The Secretary, Department Of Health And Human Services
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The U.S.A. As Represented By The Secretary, Department Of Health And Human Services filed Critical The U.S.A. As Represented By The Secretary, Department Of Health And Human Services
Publication of HRP20221183T1 publication Critical patent/HRP20221183T1/hr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/32—T-cell receptors [TCR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/82—Translation products from oncogenes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57557—Immunoassay; Biospecific binding assay; Materials therefor for cancer of other specific parts of the body, e.g. brain
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • C12N2015/8518—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic expressing industrially exogenous proteins, e.g. for pharmaceutical use, human insulin, blood factors, immunoglobulins, pseudoparticles
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
    • G01N2333/7051—T-cell receptor (TcR)-CD3 complex

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biotechnology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Toxicology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Epidemiology (AREA)
  • Plant Pathology (AREA)
HRP20221183TT 2016-08-02 2017-07-31 T-stanični receptori anti-kras-g12d HRP20221183T1 (hr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662369883P 2016-08-02 2016-08-02
PCT/US2017/044615 WO2018026691A1 (en) 2016-08-02 2017-07-31 Anti-kras-g12d t cell receptors
EP17749580.1A EP3494133B1 (en) 2016-08-02 2017-07-31 Anti-kras-g12d t cell receptors

Publications (1)

Publication Number Publication Date
HRP20221183T1 true HRP20221183T1 (hr) 2022-12-09

Family

ID=59564253

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20221183TT HRP20221183T1 (hr) 2016-08-02 2017-07-31 T-stanični receptori anti-kras-g12d

Country Status (20)

Country Link
US (6) US10611816B2 (enExample)
EP (2) EP3494133B1 (enExample)
JP (4) JP6993402B2 (enExample)
KR (1) KR102527052B1 (enExample)
CN (2) CN118063591A (enExample)
AU (3) AU2017306038B2 (enExample)
CY (1) CY1125601T1 (enExample)
DK (1) DK3494133T3 (enExample)
ES (1) ES2928051T3 (enExample)
HR (1) HRP20221183T1 (enExample)
HU (1) HUE060121T2 (enExample)
IL (2) IL301894B2 (enExample)
LT (1) LT3494133T (enExample)
PL (1) PL3494133T3 (enExample)
PT (1) PT3494133T (enExample)
RS (1) RS63615B1 (enExample)
SG (2) SG11201900654QA (enExample)
SI (1) SI3494133T1 (enExample)
SM (1) SMT202200379T1 (enExample)
WO (1) WO2018026691A1 (enExample)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11201900654QA (en) * 2016-08-02 2019-02-27 Us Health Anti-kras-g12d t cell receptors
GB201700621D0 (en) 2017-01-13 2017-03-01 Guest Ryan Dominic Method,device and kit for the aseptic isolation,enrichment and stabilsation of cells from mammalian solid tissue
AU2018335274B2 (en) 2017-09-20 2025-02-13 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services HLA class II–restricted T cell receptors against mutated RAS
US12227554B2 (en) 2017-10-05 2025-02-18 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods for selectively expanding cells expressing a TCR with a murine constant region
SG11202012653XA (en) * 2018-06-19 2021-01-28 Biontech Us Inc Neoantigens and uses thereof
CA3127673A1 (en) * 2019-01-25 2020-07-30 The Trustees Of The University Of Pennsylvania Compositions and methods for targeting mutant ras
GB2613715B (en) 2019-02-20 2023-12-06 Fred Hutchinson Cancer Center Binding proteins specific for RAS neoantigens and uses thereof
CN110172089B (zh) * 2019-06-11 2020-01-07 北京鼎成肽源生物技术有限公司 一种kras突变多抗原组合、靶向kras突变肿瘤ctl及其应用
CN112110995A (zh) * 2019-06-19 2020-12-22 上海交通大学医学院 肿瘤新抗原多肽及其用途
EP3786178A1 (en) 2019-08-30 2021-03-03 Max-Delbrück-Centrum für Molekulare Medizin in der Helmholtz-Gemeinschaft Tcr constructs specific for ebv-derived antigens
CN112760290A (zh) * 2019-10-21 2021-05-07 郑州大学 携带突变的肿瘤驱动基因的干细胞及其用途
CN112759641B (zh) * 2019-11-01 2023-01-20 香雪生命科学技术（广东）有限公司 一种识别Kras G12V的高亲和力TCR
JP7857860B2 (ja) * 2019-11-05 2026-05-13 ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム Ｈｌａ拘束性ｈｏｒｍａｄ１ ｔ細胞受容体およびその使用
JP2023507432A (ja) 2019-12-20 2023-02-22 インスティル バイオ （ユーケイ） リミテッド 腫瘍浸潤リンパ球を単離するためのデバイスおよび方法ならびにそれらの使用
EP4086281A4 (en) * 2019-12-30 2024-02-14 China Immunotech (Beijing) Biotechnology Co., Ltd IMPROVED STAR T CELL RECEPTOR AND ITS APPLICATION
CA3168015A1 (en) * 2020-02-12 2021-08-19 Noam LEVIN Hla class i-restricted t cell receptors against ras with g12d mutation
MX2022009825A (es) * 2020-02-14 2022-10-13 Us Health Receptores de células t restringidas por hla de la clase i contra ras con mutación g12v.
US20230159614A1 (en) * 2020-02-26 2023-05-25 The United States Of America,As Represented By The Secretary,Department Of Health And Human Services Hla class ii-restricted t cell receptors against ras with g12v mutation
EP4159768A4 (en) * 2020-05-25 2024-11-20 Bristar Immunotech Limited Enhanced synthetic t-cell receptor and antigen receptor
CA3185241A1 (en) 2020-07-13 2022-01-20 Noam LEVIN Hla class ii?restricted drb t cell receptors against ras with g12d mutation
CN112300269B (zh) * 2020-09-29 2022-12-09 中国科学院微生物研究所 Kras突变特异性t细胞受体筛选及抗肿瘤用途
AU2021351710A1 (en) * 2020-10-02 2023-06-08 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Hla class ii-restricted dq t cell receptors against ras with g13d mutation
JP7829242B2 (ja) * 2020-11-20 2026-03-13 シンク・セラピューティクス・インコーポレイテッド 最適化ペプチドワクチンの組成物および方法
EP4251177A4 (en) * 2020-11-25 2025-01-08 Geneius Biotechnology, Inc. Antigen specific t cells and methods of making and using same
JP2024507929A (ja) 2021-02-25 2024-02-21 アラウノス セラピューティクス インコーポレイテッド 多シストロン性発現カセットを含む組換えベクター及びそれらの使用方法
WO2022233956A1 (en) 2021-05-05 2022-11-10 Immatics Biotechnologies Gmbh Antigen binding proteins specifically binding prame
WO2023150562A1 (en) 2022-02-01 2023-08-10 Alaunos Therapeutics, Inc. Methods for activation and expansion of t cells
CN114920823B (zh) * 2022-05-27 2023-10-17 重庆医科大学 Tcr或其抗原结合片段及其应用
WO2024020537A2 (en) * 2022-07-22 2024-01-25 Board Of Regents, The University Of Texas System Cd3-expressing natural killer cells with enhanced function for adoptive immunotherapy
CN115850444B (zh) * 2022-09-15 2025-01-28 重庆医科大学 Tcr或其抗原结合片段及其应用
CN117777270B (zh) * 2022-09-29 2025-04-25 广州医科大学 一种t细胞受体(tcr)及其用途
JP2026501145A (ja) * 2022-12-13 2026-01-14 ビオンテック ユーエス インコーポレイテッド Ｔ細胞受容体構築物およびその使用
AU2024309123A1 (en) 2023-06-28 2026-01-15 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services T cell receptors targeting ras with g12d, g12r, or g12v mutation
CN120157754A (zh) * 2023-12-14 2025-06-17 新景智源生物科技(苏州)有限公司 Kras_g12d突变抗原特异性tcr及其与cd8共表达重定向cd4 t细胞
WO2025259799A2 (en) * 2024-06-12 2025-12-18 Biontech Us Inc. T cell receptor compositions and methods of use thereof

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5776459A (en) * 1989-07-19 1998-07-07 Connetics Corporation TCR V beta 5 peptides
US20020150891A1 (en) * 1994-09-19 2002-10-17 Leroy E. Hood Diagnostic and therapeutic compositions and methods which utilize the t cell receptor beta gene region
US7709002B1 (en) 1996-04-19 2010-05-04 The United States Of America As Represented By The Department Of Health And Human Services Mutated ras peptides for generation of CD8+Cytotoxic T lymphocytes
GB2328689A (en) 1997-08-27 1999-03-03 Norsk Hydro As Peptides based on the p21 ras proto-oncogene protein for the treatment of cancer
US8034334B2 (en) 2002-09-06 2011-10-11 The United States Of America As Represented By The Secretary, Department Of Health And Human Services Immunotherapy with in vitro-selected antigen-specific lymphocytes after non-myeloablative lymphodepleting chemotherapy
CA2674445C (en) 2007-01-12 2016-06-07 Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Gp100-specific t cell receptors and related materials and methods of use
US8383099B2 (en) 2009-08-28 2013-02-26 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Adoptive cell therapy with young T cells
ES2635335T3 (es) * 2010-09-20 2017-10-03 Biontech Cell & Gene Therapies Gmbh Receptores de células T específicos de antígeno y epítopos de células T
US20120244133A1 (en) 2011-03-22 2012-09-27 The United States of America, as represented by the Secretary, Department of Health and Methods of growing tumor infiltrating lymphocytes in gas-permeable containers
SI2755997T1 (sl) 2011-09-15 2018-11-30 The United States of America, as represented by Secretary, Department of Health and Human Services, Office of Technology Transfer, National Institutes of Health T-celični receptorji, ki prepoznajo HLA-A1- ali HLA-CW7-omejeni mage
US20140137274A1 (en) * 2011-11-30 2014-05-15 Lsip, Llc Induced malignant stem cells
AU2014276440A1 (en) * 2013-06-03 2015-11-05 Novartis Ag Combinations of an anti-PD-L1 antibody and a MEK inhibitor and/or a BRaf inhibitor
GB201313377D0 (en) * 2013-07-26 2013-09-11 Adaptimmune Ltd T cell receptors
GB201314404D0 (en) * 2013-08-12 2013-09-25 Immunocore Ltd T Cell Receptors
SG10201913978RA (en) 2014-11-26 2020-03-30 The United States Of America As Represented By The Secretary Anti-mutated kras t cell receptors
SG10201913868XA (en) 2015-09-15 2020-03-30 The United States Of America As Represented By The Secretary T cell receptors recognizing hla-cw8 restricted mutated kras
SG11201900654QA (en) * 2016-08-02 2019-02-27 Us Health Anti-kras-g12d t cell receptors
AU2024309123A1 (en) 2023-06-28 2026-01-15 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services T cell receptors targeting ras with g12d, g12r, or g12v mutation

Also Published As

Publication number Publication date
US20200247869A1 (en) 2020-08-06
SG10201913959WA (en) 2020-03-30
EP4159751A1 (en) 2023-04-05
JP2025090690A (ja) 2025-06-17
US11208456B2 (en) 2021-12-28
WO2018026691A1 (en) 2018-02-08
EP3494133A1 (en) 2019-06-12
SI3494133T1 (sl) 2022-11-30
EP3494133B1 (en) 2022-07-06
IL301894B1 (en) 2024-10-01
IL264425B1 (en) 2023-05-01
JP2022050400A (ja) 2022-03-30
US11840561B2 (en) 2023-12-12
AU2017306038B2 (en) 2023-06-22
CA3032870A1 (en) 2018-02-08
IL301894A (en) 2023-06-01
IL264425B2 (en) 2023-09-01
KR102527052B1 (ko) 2023-04-27
EP4159751B1 (en) 2026-07-08
AU2023233125B2 (en) 2025-10-16
US20210300988A1 (en) 2021-09-30
US20220089677A1 (en) 2022-03-24
US20190177395A1 (en) 2019-06-13
JP7413338B2 (ja) 2024-01-15
PT3494133T (pt) 2022-09-28
JP2024045139A (ja) 2024-04-02
US20250340611A1 (en) 2025-11-06
AU2023233125A1 (en) 2023-10-12
IL301894B2 (en) 2025-02-01
KR20190064566A (ko) 2019-06-10
US10611816B2 (en) 2020-04-07
IL264425A (enExample) 2019-03-31
HUE060121T2 (hu) 2023-01-28
US12391742B2 (en) 2025-08-19
CN109790211B (zh) 2024-03-26
AU2017306038A1 (en) 2019-02-14
AU2026200276A1 (en) 2026-02-19
CN109790211A (zh) 2019-05-21
RS63615B1 (sr) 2022-10-31
CY1125601T1 (el) 2026-02-25
DK3494133T3 (da) 2022-09-19
CN118063591A (zh) 2024-05-24
US20240209059A1 (en) 2024-06-27
US11897933B2 (en) 2024-02-13
JP7649370B2 (ja) 2025-03-19
SMT202200379T1 (it) 2022-11-18
PL3494133T3 (pl) 2022-11-21
JP2019527555A (ja) 2019-10-03
JP6993402B2 (ja) 2022-02-03
SG11201900654QA (en) 2019-02-27
LT3494133T (lt) 2022-12-12
ES2928051T3 (es) 2022-11-15

Similar Documents

Publication Publication Date Title
JP2019527555A5 (enExample)
HRP20200325T1 (hr) T-stanični receptori koji prepoznaju mhc razred ii-ograničenog mage-a3
IL301894B1 (en) Anti-kras-g12d t cell receptors
Feng et al. Mammalian protein arginine methyltransferase 7 (PRMT7) specifically targets RXR sites in lysine-and arginine-rich regions
Panas et al. Viral and cellular proteins containing FGDF motifs bind G3BP to block stress granule formation
JP2015535816A5 (enExample)
Cook et al. FBXO11/PRMT9, a new protein arginine methyltransferase, symmetrically dimethylates arginine residues
MY202029A (en) T-cell modulatory multimeric polypeptides and methods of use thereof
PE20230486A1 (es) Polipeptidos y sus usos
BR112022010153A2 (pt) Peptídeos, ácido nucleico, polipeptídeo, composição, complexo bioluminescente, métodos, dipeptídeo, sistema e kit
ES2662402T3 (es) Neurotoxinas recombinantes de Clostridium botulinum
BR112021018734A2 (pt) Receptores de células t e métodos de uso destes
WO2019191633A3 (en) Lysin-antimicrobial peptide (amp) polypeptide constructs, lysins, isolated polynucleotides encoding same and uses thereof
CY1118664T1 (el) Απομονωμενο πολυπεπτιδιο των πρωτεϊνων τοξινης α και τοξινης β toy c. difficile και χρησεις αυτου
BR112021017467A2 (pt) Receptores de células t e métodos de uso dos mesmos
AR059300A1 (es) Peptidos inhibidores de la fusion de vih con propiedades biologicas mejoradas
HRP20251020T1 (hr) Proteini s jednolančanim varijabilnim fragmentom koji vežu cd3
WO2017151818A3 (en) T-cell modulatory multimeric polypeptides and methods of use thereof
BR112017015567A2 (pt) proteína gl de citomegalovírus recombinante ou fragmento de formação de complexo da mesma, complexo de citomegalovírus, ácido nucleico isolado, célula hospedeira, e, composição imunogênica
WO2008039818A3 (en) Modified t cell receptors and related materials and methods
NZ737844A (en) Vista regulatory t cell mediator protein, vista binding agents and use thereof
CL2011000086A1 (es) Anticuerpo aislado o proteina funcional contra el polipeptido baffr que inhibe la proliferacion de celulas b; secuencia nucleotidicas de dicho anticuerpo; vector y celula huesped que comprende dicha secuencia; y su uso para tratar enfermedades autoinmunes o neoplasias de celulas b.
MX2021015877A (es) Receptores de celulas t que reconocen la mutacion r175h o y220c en p53.
BR112021017479A2 (pt) Receptores de células t e métodos de uso dos mesmos
BR112021017464A2 (pt) Receptores de células t e métodos de uso dos mesmos